|
1
|
Mill C and George SJ: Wnt signalling in
smooth muscle cells and its role in cardiovascular disorders.
Cardiovasc Res. 95:233–240. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rensen SS, Doevendans PA and van Eys GJ:
Regulation and characteristics of vascular smooth muscle cell
phenotypic diversity. Neth Heart J. 15:100–108. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dumic J, Dabelic S and Flögel M:
Galectin-3: An open-ended story. Biochim Biophys Acta.
1760:616–635. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Markowska AI, Liu FT and Panjwani N:
Galectin-3 is an important mediator of VEGF- and bFGF-mediated
angiogenic response. J Exp Med. 207:1981–1993. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Anand IS, Rector TS, Kuskowski M, Adourian
A, Muntendam P and Cohn JN: Baseline and serial measurements of
galectin-3 in patients with heart failure: Relationship to
prognosis and effect of treatment with valsartan in the Val-HeFT.
Eur J Heart Fail. 15:511–518. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Calvier L, Miana M, Reboul P, Cachofeiro
V, Martinez-Martinez E, de Boer RA, Poirier F, Lacolley P, Zannad
F, Rossignol P and López-Andrés N: Galectin-3 mediates
aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc
Biol. 33:67–75. 2013. View Article : Google Scholar
|
|
7
|
Morrow DA and O'Donoghue ML: Galectin-3 in
cardiovascular disease: A possible window into early myocardial
fibrosis. J Am Coll Cardiol. 60:1257–1258. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wesley UV, Vemuganti R, Ayvaci ER and
Dempsey RJ: Galectin-3 enhances angiogenic and migratory potential
of microglial cells via modulation of integrin linked kinase
signaling. Brain Res. 1496:1–9. 2013. View Article : Google Scholar
|
|
9
|
Arar C, Gaudin JC, Capron L and Legrand A:
Galectin-3 gene (LGALS3) expression in experimental atherosclerosis
and cultured smooth muscle cells. FEBS Lett. 430:307–311. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Massaeli H, Hurtado C, Austria JA and
Pierce GN: Oxidized low-density lipoprotein induces cytoskeletal
disorganization in smooth muscle cells. Am J Physiol.
277:H2017–H2025. 1999.PubMed/NCBI
|
|
11
|
Obradovic MM, Trpkovic A, Bajic V, Soskic
S, Jovanovic A, Stanimirovic J, Panic M and Isenovic ER:
Interrelatedness between C-reactive protein and oxidized
low-density lipoprotein. Clin Chem Lab Med. 53:29–34. 2015.
View Article : Google Scholar
|
|
12
|
Steinberg D: Oxidized low density
lipoprotein - an extreme example of lipoprotein heterogeneity. Isr
J Med Sci. 32:469–472. 1996.PubMed/NCBI
|
|
13
|
Auge N, Garcia V, Maupas-Schwalm F, Levade
T, Salvayre R and Negre-Salvayre A: Oxidized LDL-induced smooth
muscle cell proliferation involves the EGF receptor/PI-3 kinase/Akt
and the sphingolipid signaling pathways. Arterioscler Thromb Vasc
Biol. 22:1990–1995. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Leavesley DI, Schwartz MA, Rosenfeld M and
Cheresh DA: Integrin beta 1- and beta 3-mediated endothelial cell
migration is triggered through distinct signaling mechanisms. J
Cell Biol. 121:163–170. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Argmann CA, Sawyez CG, Li S, Nong Z,
Hegele RA, Pickering JG and Huff MW: Human smooth muscle cell
subpopulations differentially accumulate cholesteryl ester when
exposed to native and oxidized lipoproteins. Arterioscler Thromb
Vasc Biol. 24:1290–1296. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
17
|
Karagiannis GS, Weile J, Bader GD and
Minta J: Integrative pathway dissection of molecular mechanisms of
moxLDL-induced vascular smooth muscle phenotype transformation. BMC
Cardiovasc Disord. 13:42013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Augé N, Maupas-Schwalm F, Elbaz M, Thiers
JC, Waysbort A, Itohara S, Krell HW, Salvayre R and Nègre-Salvayre
A: Role for matrix metalloproteinase-2 in oxidized low-density
lipoprotein-induced activation of the sphingomyelin/ceramide
pathway and smooth muscle cell proliferation. Circulation.
110:571–578. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Guyton JR, Lenz ML, Mathews B, Hughes H,
Karsan D, Selinger E and Smith CV: Toxicity of oxidized low density
lipoproteins for vascular smooth muscle cells and partial
protection by antioxidants. Atherosclerosis. 118:237–249. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Deng DX, Spin JM, Tsalenko A, Vailaya A,
Ben-Dor A, Yakhini Z, Tsao P, Bruhn L and Quertermous T: Molecular
signatures determining coronary artery and saphenous vein smooth
muscle cell phenotypes: Distinct responses to stimuli. Arterioscler
Thromb Vasc Biol. 26:1058–1065. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ding Z, Liu S, Yang B, Fan Y and Deng X:
Effect of oxidized low-density lipoprotein concentration
polarization on human smooth muscle cells' proliferation, cycle,
apoptosis and oxidized low-density lipoprotein uptake. J R Soc
Interface. 9:1233–1240. 2012. View Article : Google Scholar :
|
|
22
|
Shimura T, Takenaka Y, Tsutsumi S, Hogan
V, Kikuchi A and Raz A: Galectin-3, a novel binding partner of
beta-catenin. Cancer Res. 64:6363–6367. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Menini S, Iacobini C, Ricci C, Blasetti
Fantauzzi C, Salvi L, Pesce CM, Relucenti M, Familiari G, Taurino M
and Pugliese G: The galectin-3/RAGE dyad modulates vascular
osteogenesis in atherosclerosis. Cardiovasc Res. 100:472–480. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim K, Mayer EP and Nachtigal M:
Galectin-3 expression in macrophages is signaled by Ras/MAP kinase
pathway and up-regulated by modified lipoproteins. Biochim Biophys
Acta. 1641:13–23. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu J, Ren Y, Kang L and Zhang L: Oxidized
low-density lipoprotein increases the proliferation and migration
of human coronary artery smooth muscle cells through the
upregulation of osteopontin. Int J Mol Med. 33:1341–1347.
2014.PubMed/NCBI
|
|
26
|
Dzau VJ, Braun-Dullaeus RC and Sedding DG:
Vascular proliferation and atherosclerosis: New perspectives and
therapeutic strategies. Nat Med. 8:1249–1256. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nachtigal M, Ghaffar A and Mayer EP:
Galectin-3 gene inactivation reduces atherosclerotic lesions and
adventitial inflammation in ApoE-deficient mice. Am J Pathol.
172:247–255. 2008. View Article : Google Scholar :
|
|
28
|
Xue JH, Yuan Z, Wu Y, Liu Y, Zhao Y, Zhang
WP, Tian YL, Liu WM, Liu Y and Kishimoto C: High glucose promotes
intracellular lipid accumulation in vascular smooth muscle cells by
impairing cholesterol influx and efflux balance. Cardiovasc Res.
86:141–150. 2010. View Article : Google Scholar
|
|
29
|
Rong JX, Shapiro M, Trogan E and Fisher
EA: Transdifferentiation of mouse aortic smooth muscle cells to a
macrophage-like state after cholesterol loading. Proc Natl Acad Sci
USA. 100:13531–13536. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Carthy JM, Luo Z and McManus BM: WNT3A
induces a contractile and secretory phenotype in cultured vascular
smooth muscle cells that is associated with increased gap junction
communication. Lab Invest. 92:246–255. 2012. View Article : Google Scholar
|
|
31
|
Hao H, Gabbiani G and Bochaton-Piallat ML:
Arterial smooth muscle cell heterogeneity: Implications for
atherosclerosis and restenosis development. Arterioscler Thromb
Vasc Biol. 23:1510–1520. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rama A, Matsushita T, Charolidi N, Rothery
S, Dupont E and Severs NJ: Up-regulation of connexin43 correlates
with increased synthetic activity and enhanced contractile
differentiation in TGF-β-treated human aortic smooth muscle cells.
Eur J Cell Biol. 85:375–386. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xie D, Yin D, Tong X, O'Kelly J, Mori A,
Miller C, Black K, Gui D, Said JW and Koeffler HP: Cyr61 is
overexpressed in gliomas and involved in integrin-linked
kinase-mediated Akt and beta-catenin-TCF/Lef signaling pathways.
Cancer Res. 64:1987–1996. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lee KB, Ye S, Park MH, Park BH, Lee JS and
Kim SM: p63-Mediated activation of the β-catenin/c-Myc signaling
pathway stimulates esophageal squamous carcinoma cell invasion and
metastasis. Cancer Lett. 353:124–132. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kim SJ, Choi IJ, Cheong TC, Lee SJ, Lotan
R, Park SH and Chun KH: Galectin-3 increases gastric cancer cell
motility by up-regulating fascin-1 expression. Gastroenterology.
138:1035–1045. 2010. View Article : Google Scholar
|
|
36
|
Kobayashi T, Shimura T, Yajima T, Kubo N,
Araki K, Tsutsumi S, Suzuki H, Kuwano H and Raz A: Transient gene
silencing of galectin-3 suppresses pancreatic cancer cell migration
and invasion through degradation of β-catenin. Int J Cancer.
129:2775–2786. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang D, Chen ZG, Liu SH, Dong ZQ, Dalin
M, Bao SS, Hu YW and Wei FC: Galectin-3 gene silencing inhibits
migration and invasion of human tongue cancer cells in vitro via
downregu-lating β-catenin. Acta Pharmacol Sin. 34:176–184. 2013.
View Article : Google Scholar
|
|
38
|
Song S, Mazurek N, Liu C, Sun Y, Ding QQ,
Liu K, Hung MC and Bresalier RS: Galectin-3 mediates nuclear
beta-catenin accumulation and Wnt signaling in human colon cancer
cells by regulation of glycogen synthase kinase-3beta activity.
Cancer Res. 69:1343–1349. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Weir RA, Petrie CJ, Murphy CA, Clements S,
Steedman T, Miller AM, McInnes IB, Squire IB, Ng LL, Dargie HJ and
McMurray JJ: Galectin-3 and cardiac function in survivors of acute
myocardial infarction. Circ Heart Fail. 6:492–498. 2013. View Article : Google Scholar : PubMed/NCBI
|
